Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of cases. It includes subtypes such as adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Non-small cell lung cancer is often diagnosed at an advanced stage, which makes treatment challenging.
The focus of NSCLC therapy development is on targeted therapy and immunotherapy.
Targeted Therapy
Target specific gene mutations that drive tumor growth.
Immunotherapy
Enhance the immune system's ability to attack cancer cells, especially immune checkpoint inhibitors.
NSCLC is characterized by high morbidity and mortality, and existing therapies cannot meet the demand for cure, so effective therapies are urgently needed. In addition, personalized medicine continues to advance, driving research and development of NSCLC therapies. At the same time, the NSCLC treatment market is large, and the development of effective drugs has significant economic return potential. Many pharmaceutical companies are actively developing drugs and therapies for NSCLC.
| Company | Drug/Therapy | Target |
| Roche | Atezolizumab | PD-L1 |
| Merck | Pembrolizumab | PD-1 |
| AstraZeneca | Osimertinib | EGFR |
| Novartis | Ceritinib | ALK |
| Bristol-Myers Squibb | Nivolumab | PD-1 |
Alfa Cytology provides one-stop pre-clinical development services for NSCLC therapies. However, according to the needs of the project, the modular services can also be customized. It includes but is not limited to the following contents.
Quick Inquiry
By Molecule Type
Depending on the molecular type, our one-stop drug/therapy development services include, but are not limited to, the following.
By Target
The therapy development of NSCLC faces great challenges. Alfa Cytology provides target discovery and corresponding targeted drug/therapy development services, which provides an important basis for personalized therapies of NSCLC.
By Research Phase
The therapy development process requires expertise and extensive project experience, and our team of experts escorts the entire development process.
As a preclinical service provider for lung cancer therapy development, Alfa Cytology is well positioned in several aspects.
Comprehensive Detection and Analysis Ability
Customized Solutions and Personalized Service
Cutting-edge Technology Support and Innovation
Senior Scientist Team and Extensive Industry experience
As a leading preclinical service provider dedicated to advancing lung cancer treatment development, Alfa Cytology has established a robust suite of cutting-edge technology platforms designed to accelerate the discovery and development of novel therapies. Our comprehensive platforms encompass state-of-the-art tools for lung cancer model development, high-throughput drug screening, multi-omics analysis, and advanced imaging and diagnostics.
What lung cancer therapy development services do you offer?
Alfa Cytology offers a full range of lung cancer therapy development services, including animal modeling, drug screening, pharmacodynamic evaluation, pharmacokinetic studies, toxicological evaluation, biomarker discovery, and multi-omics analysis.
What is the process for starting a project?
You can contact us by phone (), email () or on our website and our team will discuss your project needs in detail and provide you with a customized study proposal and quotation. In addition, we need to know your specific research objectives, budget, schedule, and any specific technical requirements or experimental design.
What animal models of lung cancer do you offer?
Alfa Cytology offers a variety of animal models of lung cancer, including chemically induced models, genetically engineered models, xenotransplantation models (PDX) and orthotopic transplantation models.
For research use only.
